Nasdaq:US$16.92 (+0.36) | HKEX:HK$26.90 (+0.85) | AIM:£2.47 (+0.03)
搜索
News & Press Releases
12345678910111213141516
17
1819
找到相关结果： 936
演示文稿, 科学出版物 | 2012-06-01

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors
公告及新闻稿, 监管通知 | 2012-05-30

Director's Shareholding
公告及新闻稿, 监管通知 | 2012-05-11

Results of Annual General Meeting
公告及新闻稿, 监管通知 | 2012-04-10

2011 Annual Report and Notice of Annual General Meeting
公告及新闻稿, 集团 | 2012-03-20

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook
公告及新闻稿, 肿瘤学 / 免疫学 | 2012-02-22

 和黄医药启动新型受体（c-Met）抑制剂沃利替尼（Volitinib）Ⅰ期临床试验
2012年2月22日： 和黄医药今日宣布在澳大利亚启动沃利替尼（HMPL-504）I期临床试验。沃利替尼是一种小分子新型靶向治疗药物，是c-Met受体酪氨酸激酶的高选择性抑制剂，用于癌症治疗。沃
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2012-02-20

Notice of Announcement of 2011 Final Results
公告及新闻稿, 监管通知 | 2012-02-14

TR-1: Notification of major interests in shares
公告及新闻稿, 监管通知 | 2012-02-02

Total Voting Rights
公告及新闻稿, 监管通知 | 2012-01-05

TR-1: Notification of major interest in shares
公告及新闻稿, 监管通知 | 2011-12-29

Blocklisting Six Monthly Return
公告及新闻稿, 肿瘤学 / 免疫学 | 2011-12-21

阿斯利康与和黄医药强联手 打造全球创新癌症治疗方案
2011年12月21日︰阿斯利康与和黄医药今日宣布，双方签署了一项合作协议，共同致力于沃利替尼(Volitinib, HMPL-504）在全球范围内的开发、审批和销售。和黄医药是一家领先的中国新药研发企业
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2011-12-12

Chi-Med Loan Facility
公告及新闻稿, 肿瘤学 / 免疫学 | 2011-11-04

和黄医药启动表皮生长因子受体（EGFR）抑制剂依吡替尼（Epitinib）Ⅰ期临床试验
2011年11月4日：和黄医药今日宣布启动依吡替尼(HMPL-813) Ⅰ期临床试验。依吡替尼是和黄医药研发项目中第三个进入国内临床试验的靶向抗肿瘤候选药物。依吡替尼是作用于表皮生长因子受体(
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2011-09-05

TR-1: Notification of major interests in shares
公告及新闻稿, 集团 | 2011-08-01

Interim Results for the Six Months Ended 30 June 2011
公告及新闻稿, 其他业务 | 2011-07-22

China Healthcare Division expands OTC drug distribution and marketing operations
公告及新闻稿, 监管通知 | 2011-07-05

Notice of Announcement of 2011 Interim Results
公告及新闻稿, 监管通知 | 2011-06-29

Blocklisting Six Monthly Return
公告及新闻稿, 监管通知 | 2011-05-13

TR-1: Notification of major interests in shares
公告及新闻稿, 监管通知 | 2011-05-09

TR-1: Notification of major interests in shares
公告及新闻稿, 监管通知 | 2011-05-09

Results of Annual General Meeting
演示文稿, 科学出版物 | 2011-04-06

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models
公告及新闻稿, 监管通知 | 2011-04-04

2010 Annual Report and Notice of Annual General Meeting
公告及新闻稿, 监管通知 | 2011-03-28

Director's Shareholding
公告及新闻稿, 集团 | 2011-03-09

Final Results for the year ended 31 December 2010 Strong performance across all divisions.
公告及新闻稿, 监管通知 | 2011-02-21

Board Change
公告及新闻稿, 监管通知 | 2011-02-15

Appointment of UBS Limited as Joint Broker
公告及新闻稿, 肿瘤学 / 免疫学 | 2011-02-01

和黄医药获SFDA批准启动呋喹替尼一期临床研究
星期二，2011年2月1日：和黄医药今日宣布在中国启动1.1类靶向抗癌新药呋喹替尼一期临床研究。同公司另一1.1类靶向抗癌新药索凡替尼一样，呋喹替尼的新药临床研究申请是通过国家药品食
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2011-01-31

Notice of Announcement of 2010 Final Results
公告及新闻稿, 监管通知 | 2011-01-05

Total Voting Rights
公告及新闻稿, 监管通知 | 2010-12-29

Blocklisting Six Monthly Return
公告及新闻稿, 肿瘤学 / 免疫学 | 2010-12-21

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline
公告及新闻稿, 其他业务 | 2010-12-10

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture
演示文稿, 科学出版物 | 2010-11-30

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)
公告及新闻稿, 肿瘤学 / 免疫学 | 2010-11-08

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline
演示文稿, 科学出版物 | 2010-10-16

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor
公告及新闻稿, 其他业务 | 2010-09-20

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China
公告及新闻稿, 监管通知 | 2010-09-15

Appointment of Joint Broker
公告及新闻稿, 集团 | 2010-07-29

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.
公告及新闻稿, 监管通知 | 2010-07-14

TR-1: Notification of major interests in shares
公告及新闻稿, 监管通知 | 2010-07-07

Notice of Announcement of 2010 Interim Results
公告及新闻稿, 监管通知 | 2010-07-07

TR-1: Notification of major interests in shares
公告及新闻稿, 监管通知 | 2010-07-05

Total Voting Rights
公告及新闻稿, 监管通知 | 2010-06-29

Blocklisting Six Monthly Return
公告及新闻稿, 监管通知 | 2010-06-25

Director's Shareholding
公告及新闻稿, 监管通知 | 2010-06-17

TR-1: Notification of major interests in shares
公告及新闻稿, 肿瘤学 / 免疫学 | 2010-04-30

和黄医药抗癌新药索凡替尼获得国家药监局新药临床试验批文
— 公司启动索凡替尼一期临床试验 和黄医药宣布启动其治疗癌症的全新候选药物索凡替尼的 I 期临床研究，第一例受试者于近日开始用药。索凡替尼的新药临床试验申请通过国家药品食品
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2010-04-30

Results of Annual General Meeting
公告及新闻稿, 其他业务 | 2010-04-19

Seven-year extension of IP protection for Chi-Med's main prescription drug
12345678910111213141516
17
1819